Calamos Advisors
IRWD icon

Calamos Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Calamos Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51K Hold
14,520
– – ﹤0.01% 1148
2025
Q4 		$48.9K Buy
+14,520
New +$37.7K ﹤0.01% 876

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Calamos Advisors's IRWD Position: Q1 2026 in Review

Calamos Advisors held its Ironwood Pharmaceuticals (IRWD) position steady in Q1 2026 at 14,520 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #1148.

Calamos Advisors first reported a position in IRWD in Q4 2025 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Calamos Advisors held 14,520 shares of Ironwood Pharmaceuticals worth $51K as of Q1 2026.
  • Calamos Advisors left its Ironwood Pharmaceuticals share count unchanged in Q1 2026.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Calamos Advisors's portfolio in Q1 2026, its #1148 holding.
  • Calamos Advisors first reported a position in Ironwood Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.